Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic International, Inc. (NASDAQ: DYAI) announced its participation in several key biotechnology events aimed at advancing its innovative C1-cell protein production platform. A notable KOL Fireside Chat is scheduled for May 4, 2021, focusing on the potential of Dyadic's technology to address global health challenges. Key Opinion Leaders will include experts from renowned institutions. Additionally, Dyadic will present at the World Vaccine Congress and PEGS Boston, discussing advancements in vaccine development and manufacturing. Dyadic's C1 technology promises lower costs and enhanced production capabilities for biologic vaccines and drugs.
Dyadic International, Inc. (NASDAQ:DYAI) will report its financial results for the first quarter of 2021 on May 13, 2021. The company is known for its proprietary C1-cell protein production platform, which aims to reduce costs and improve the efficiency of biologic vaccines and drugs. A corporate update conference call is scheduled for 5:00 p.m. Eastern Time on the same day. The call will be accessible via a toll-free number or webcast, with an archive available on Dyadic's website shortly after the event.
Dyadic International (NASDAQ: DYAI) is hosting a fireside chat on May 4, 2021, at 10:00 AM ET to discuss its proprietary C1 protein production platform. This event will feature key opinion leaders from renowned institutions, discussing the platform's benefits, regulatory advantages, and case studies including successful antigen production for viruses. Dyadic aims to leverage the C1 platform to develop cost-effective, scalable solutions for vaccines and therapeutics, addressing global health challenges and emerging SARS-CoV-2 variants. Registration is available online.
Dyadic announced advancement of its COVID-19 vaccine candidate, DYAI-100, towards Phase 1 clinical trials, validating safety in humans. They've expanded partnerships in Korea and Southeast Asia with Medytox for next-gen variant vaccines. Cash reserves stand at $29.2 million as of December 31, 2020. The PR highlights increased R&D expenses to $3.87 million and a net loss of approximately $9.3 million for 2020. Despite a revenue decline to $1.6 million, the company is pursuing multiple collaborations and projects in infectious disease vaccines.
Dyadic International is advancing its proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial. The company has partnered with CR2O to validate the safety of C1 produced proteins and support further development. This step aims to create next-generation variant vaccines. Additionally, Dyadic has expanded its partnership with Medytox in Korea and Southeast Asia for next-gen COVID-19 vaccines. DYAI-100 has shown promising interim results with substantial immunogenicity in animal studies, prompting the engineering of new C1 cell lines for broader efficacy against emerging variants.
Dyadic International (NASDAQ: DYAI) announced an expansion of its partnership with Medytox to co-develop C1-manufactured COVID-19 vaccines. This collaboration aims to create vaccines that target multiple COVID-19 variants, including potential tetravalent and quadrivalent options. The project will provide local supply within the Republic of Korea and several Southeast Asian countries. Successful manufacturing protocols for the C1 technology have been transferred to Medytox, enhancing the capabilities for producing effective vaccines.
Dyadic International (NASDAQ: DYAI) has announced an expansion of its collaboration with Medytox, aimed at co-developing C1-enabled COVID-19 vaccines and boosters. This partnership, which began in July 2020, will target immunization against multiple COVID-19 variants. Dyadic has successfully transferred manufacturing protocols to Medytox, and if successful, the project will grant exclusive licensing rights for the Republic of Korea and Southeast Asia. The C1 platform is recognized for its potential in producing affordable, high-volume biologic products.
Dyadic announced progress in its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100. Successful challenge studies in human ACE2 transgenic mice indicated high neutralizing antibody levels, supporting potential efficacy. The vaccine is set for a Phase 1 clinical trial, anticipated to start in 2H 2021, managed by CR2O. This collaboration aims to develop scalable and affordable vaccines against COVID-19 variants. Dyadic is also engineering additional cell lines for variant-specific antigens, enhancing its market position.
Dyadic International, Inc. (NASDAQ:DYAI) will report its financial results for the full year ended December 31, 2020, on March 30, 2021. The results will be followed by a corporate update conference call at 5:00 p.m. ET. Dyadic specializes in a proprietary C1-cell protein production platform aimed at reducing costs and accelerating the development of biologic vaccines and drugs. The company envisions that its technology will enhance the performance of biopharmaceuticals, improving access and affordability in healthcare.
Dyadic International (NASDAQ: DYAI) reported significant achievements in its C1 platform regarding vaccine production in animal trials. The platform yielded 300 times more Schmallenberg virus antigens than traditional methods, proving safety and efficacy. Dyadic's involvement in the €20 million Zoonotic Anticipation and Preparedness Initiative (ZAPI) has led to ongoing fully funded animal trials and SARS-CoV-2 vaccine collaborations, positioning the company for a potential human Phase 1 clinical program. Their C1 technology shows promise for lower-cost biological drug production.